SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC).
Toni K. Choueiri(Harvard University), Laurence Albigès(Université Paris-Saclay), Lone H. Ottesen(AstraZeneca (United Kingdom)), Remy B. Verheijen(AstraZeneca (United Kingdom)), Sabina Signoretti(Brigham and Women's Hospital), Anders Mellemgaard(AstraZeneca (United Kingdom)), Jae‐Lyun Lee(Ulsan College), Anne L’Hernault(AstraZeneca (United Kingdom)), Zsolt Szíjgyártó(AstraZeneca (United Kingdom)), Mathilde Cancel(Centre Hospitalier Universitaire de Tours), Daniel Yick Chin Heng(University of Calgary), Melanie M. Frigault(Vifor Pharma (United States))
Cited by 5
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k